AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12523585 — intervention group
Group type: EXPERIMENTAL
Intervention: RBC 400 mg, clarithromycin (C) 250 mg, metronidazole (M) 500 mg (RBC.C.M)
Number of subjects: 426
Study 12523585 — intervention group
Group type: EXPERIMENTAL
Intervention: RBC 400 mg, tetracycline (T) 1000 mg, metronidazole (M) 500 mg (RBC.T.M)
Number of subjects: 426
Study 10375099 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronomodulated 5‐FU (700 mg/m2/day), LV (300 mg/m2/day), and 1‐OHP (25 mg/m2/day) for 4 days every 14 days.
Number of subjects: 90
Study 8600888 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone Study Classification System
Number of subjects: 287
Study 8600888 — intervention group
Group type: EXPERIMENTAL
Intervention: Retina Society Classification System
Number of subjects: 287
Study 1767242 — intervention group
Group type: EXPERIMENTAL
Intervention: Aniracetam (1500 mg/day per os)
Number of subjects: 60
Study 1767242 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 6412896 — intervention group
Group type: EXPERIMENTAL
Intervention: terbutaline sulphate
Number of subjects: 30
Study 6412896 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study 30665504 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 L of normal saline solution during 1 hour
Number of subjects: 49
Study 30665504 — intervention group
Group type: COMPARATOR
Intervention: Saline solution at 10 mL/hour for 1 hour (control group)
Number of subjects: 49
Study 27858693 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiotape
Number of subjects: 2
Study 27858693 — intervention group
Group type: COMPARATOR
Intervention: Sham tape (control)
Number of subjects: 2
Study 25274266 — intervention group
Group type: EXPERIMENTAL
Intervention: LDRnHBT (Low-dose radon hyperthermia balneo treatment)
Number of subjects: 0
Study 25274266 — intervention group
Group type: COMPARATOR
Intervention: PlaceboHBT (radon-free thermal water)
Number of subjects: 0
Study 25274266 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined hyperthermia balneo and exercise treatment
Number of subjects: 0
Study 24930817 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-calorie weight-loss diet and exercise program
Number of subjects: 300
Study 24930817 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 300
Study 22870723 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified skin flap of external canal
Number of subjects: 412
Study 22870723 — intervention group
Group type: COMPARATOR
Intervention: Traditional skin flap of external canal
Number of subjects: 412
Study 19324944 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorogenic acid (1 g)
Number of subjects: 15
Study 19324944 — intervention group
Group type: EXPERIMENTAL
Intervention: Trigonelline (500 mg)
Number of subjects: 15
Study 19324944 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 g mannitol)
Number of subjects: 15
Study 16839826 — intervention group
Group type: EXPERIMENTAL
Intervention: PariLC+ nebuliser
Number of subjects: 10
Study 16839826 — intervention group
Group type: COMPARATOR
Intervention: NL9M nebuliser
Number of subjects: 10
Study 15157948 — intervention group
Group type: COMPARATOR
Intervention: FMS patients
Number of subjects: 40
Study 15157948 — intervention group
Group type: COMPARATOR
Intervention: CFS patients
Number of subjects: 40
Study 15157948 — intervention group
Group type: COMPARATOR
Intervention: Pulsatility analyses
Number of subjects: 40
Study 11522582 — intervention group
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (GA) 20 mg daily subcutaneous injections
Number of subjects: 233
Study 11522582 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 233
Study 11522582 — intervention group
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (GA)
Number of subjects: 233
Study 9928557 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposuction and axilloscopy
Number of subjects: 50
Study 7920875 — intervention group
Group type: EXPERIMENTAL
Intervention: Very Low Calorie Diet (VLCD, 514 and 470 Kcal/day in women and men respectively)
Number of subjects: 52
Study 7920875 — intervention group
Group type: COMPARATOR
Intervention: Control group (baseline measurements)
Number of subjects: 52
Study 3291074 — intervention group
Group type: EXPERIMENTAL
Intervention: High doses of diethylcarbamazine (DEC) - 30 mg/kg/d for one week preceded by a one week initial treatment with normal oral doses of DEC or DEC lotion
Number of subjects: 50
Study 3291074 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of ivermectin (150 micrograms/kg)
Number of subjects: 50
Study 3291074 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 31789711 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril-valsartan (ARNI)
Number of subjects: 2165
Study 31789711 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully eligible patients
Number of subjects: 2165
Study 31789711 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially eligible patients
Number of subjects: 2165
Study 31789711 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully and partially eligible patients
Number of subjects: 2165
Study 29420189 — intervention group
Group type: EXPERIMENTAL
Intervention: DOUBLE (double-dose clopidogrel)
Number of subjects: 1078
Study 29420189 — intervention group
Group type: EXPERIMENTAL
Intervention: TRIPLE (adjunctive cilostazol)
Number of subjects: 1078
Study 29420189 — intervention group
Group type: COMPARATOR
Intervention: STANDARD (standard dual antiplatelet therapy)
Number of subjects: 1078
Study 29420189 — intervention group
Group type: EXPERIMENTAL
Intervention: DOUBLE
Number of subjects: 1078
Study 29420189 — intervention group
Group type: EXPERIMENTAL
Intervention: TRIPLE
Number of subjects: 1078
Study 28737440 — intervention group
Group type: EXPERIMENTAL
Intervention: secukinumab 300 mg
Number of subjects: 102
Study 28737440 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 102
Study 26248059 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle
Number of subjects: 132
Study 26248059 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiocath
Number of subjects: 132
Study 26248059 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 132
Study 24088688 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration of family planning services into HIV care and treatment clinics
Number of subjects: 12
Study 24088688 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care with separately delivered family planning and HIV services
Number of subjects: 12
Study 20505750 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of L-NMMA
Number of subjects: 10
Study 20505750 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 10
Study 19081890 — intervention group
Group type: EXPERIMENTAL
Intervention: Vector system (Durr Dental)
Number of subjects: 41
Study 19081890 — intervention group
Group type: COMPARATOR
Intervention: Handheld instruments
Number of subjects: 41
Study 16624583 — intervention group
Group type: EXPERIMENTAL
Intervention: Looking at pictures of abstract art with no explicit instruction to remember
Number of subjects: 20
Study 16624583 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit instruction to remember the stimuli
Number of subjects: 20
Study 12356000 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamid SR 1.5 mg
Number of subjects: 524
Study 12356000 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg
Number of subjects: 524
Study 12356000 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 25 mg
Number of subjects: 524
Study 10583349 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg
Number of subjects: 1366
Study 10583349 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 16 mg
Number of subjects: 1366
Study 10583349 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide 10 mg
Number of subjects: 1366
Study 8756842 — intervention group
Group type: EXPERIMENTAL
Intervention: Transanal mucosectomy with handsewn anastomosis (Group I, 13 cases)
Number of subjects: 40
Study 8756842 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-stapled technique (Group II, 15 cases)
Number of subjects: 40
Study 8756842 — intervention group
Group type: COMPARATOR
Intervention: Double-stapled anastomosis with preservation of the anal transition zone (Group III, 12 cases)
Number of subjects: 40
Study 1918848 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraportal nitroglycerin (1 microgram/kg/min)
Number of subjects: 18
Study 1918848 — intervention group
Group type: COMPARATOR
Intervention: Intravenous nitroglycerin (1 microgram/kg/min)
Number of subjects: 18
Study 7036801 — intervention group
Group type: EXPERIMENTAL
Intervention: Ancrod (Arvin)
Number of subjects: 27
Study 7036801 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 27
Study 29073785 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprostadil
Number of subjects: 300
Study 29073785 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 300
Study 27091717 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose corticosteroid prophylaxis (group B, n = 72)
Number of subjects: 228
Study 27091717 — intervention group
Group type: COMPARATOR
Intervention: No corticosteroid prophylaxis (group C, n = 73)
Number of subjects: 228
Study 27091717 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose corticosteroid prophylaxis (group B)
Number of subjects: 228
Study 25608587 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid treatment
Number of subjects: 263
Study 25608587 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 263
Study 25608587 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative or indeterminate IGRA results
Number of subjects: 263
Study 23930203 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid liposomes (HL-23)
Number of subjects: 0
Study 21039933 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic extract supplementation at 250 mg/kg BW/day/calf
Number of subjects: 12
Study 21039933 — intervention group
Group type: COMPARATOR
Intervention: Control group (no garlic extract)
Number of subjects: 12
Study 18560524 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentrated ambient fine and ultrafine particles (CAPs)
Number of subjects: 24
Study 18560524 — intervention group
Group type: COMPARATOR
Intervention: Filtered air (Control)
Number of subjects: 24
Study 16775418 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (100 mg/m(2))
Number of subjects: 7
Study 16775418 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (15 mg/m(2)) with ketoconazole (400 mg 3 times daily)
Number of subjects: 7
Study 12705363 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotropin ZipTip needle-free device
Number of subjects: 133
Study 12705363 — intervention group
Group type: COMPARATOR
Intervention: Genotropin Pen (fine-gauge needle)
Number of subjects: 133
Study 11253342 — intervention group
Group type: EXPERIMENTAL
Intervention: External compression (intermittent by pneumatic pumps, continuous by anelastic or elastic bandages, and graduated compression stockings)
Number of subjects: 0
Study 11253342 — intervention group
Group type: EXPERIMENTAL
Intervention: External compression
Number of subjects: 0
Study 11253342 — intervention group
Group type: EXPERIMENTAL
Intervention: External compression with early mobilization and Low Molecular Weight Heparin (LMWH) therapy
Number of subjects: 0
Study 9189045 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (up to 900 mg/day)
Number of subjects: 21
Study 9189045 — intervention group
Group type: COMPARATOR
Intervention: Baclofen (up to 30 mg/day)
Number of subjects: 21
Study 7694617 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Kleinert dynamic splint
Number of subjects: 37
Study 7694617 — intervention group
Group type: COMPARATOR
Intervention: Original Kleinert dynamic splint
Number of subjects: 37
Study 3697615 — intervention group
Group type: EXPERIMENTAL
Intervention: d(15)+Be neutrons
Number of subjects: 34
Study 3697615 — intervention group
Group type: COMPARATOR
Intervention: 4 MV photons
Number of subjects: 34
Study 30457433 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate/eFlow CS 50 μg twice daily
Number of subjects: 620
Study 30457433 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium 18 μg once daily (administered via HandiHaler™)
Number of subjects: 620
Study 28544344 — intervention group
Group type: EXPERIMENTAL
Intervention: MPH XR-ODT (60 mg) administered in a fed state
Number of subjects: 48
Study 28544344 — intervention group
Group type: COMPARATOR
Intervention: MPH XR-ODT (60 mg) administered in a fasted state
Number of subjects: 48
Study 28544344 — intervention group
Group type: EXPERIMENTAL
Intervention: MPH XR-ODT (60 mg)
Number of subjects: 48
Study 26152608 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient intervention (Phase 1)
Number of subjects: 120
Study 26152608 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider intervention (Phase 2)
Number of subjects: 120
Study 26152608 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient intervention only (Phase 1)
Number of subjects: 120
Study 26152608 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 120
Study 25306591 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal bone mass
Number of subjects: 83
Study 25306591 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopenia
Number of subjects: 83
Study 25306591 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoporosis
Number of subjects: 83
Study 22353395 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 86-6150 (6.5, 20, 50 or 90 μg kg(‐1))
Number of subjects: 16
Study 22353395 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 20826592 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning (rIC) - 4 cycles of 5 minutes upper-limb ischemia during transfer to primary percutaneous coronary intervention (pPCI)
Number of subjects: 242
Study 20826592 — intervention group
Group type: COMPARATOR
Intervention: pPCI alone
Number of subjects: 242
Study 20826592 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning (rIC)
Number of subjects: 242
Study 18853615 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirazid (10 mg/kg for 2 weeks)
Number of subjects: 60
Study 18853615 — intervention group
Group type: EXPERIMENTAL
Intervention: Paromomycin (500 mg qid for 2 weeks)
Number of subjects: 60
Study 18853615 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Mirazid (10 mg/kg) and Paromomycin (500 mg) for two weeks
Number of subjects: 60
Study 18853615 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study 15668467 — intervention group
Group type: EXPERIMENTAL
Intervention: R‐CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)
Number of subjects: 122
Study 15668467 — intervention group
Group type: COMPARATOR
Intervention: CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)
Number of subjects: 122
Study 12827065 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 0
Study 12827065 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 0
Study 12827065 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulants (general)
Number of subjects: 0
Study 10669150 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily 2 mg micronised oestradiol (E2)
Number of subjects: 60
Study 10669150 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily 2 mg micronised oestradiol combined with a progestagen for 14 days of each cycle (E2+P)
Number of subjects: 60
Study 10669150 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily 2 mg micronised oestradiol (E2) and E2+P
Number of subjects: 60
Study 10669150 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 60
Study 8797400 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol and ipratropium (2.5 mg albuterol + 0.5 mg ipratropium)
Number of subjects: 384
Study 8797400 — intervention group
Group type: COMPARATOR
Intervention: Albuterol alone (2.5 mg)
Number of subjects: 384
Study 1468911 — intervention group
Group type: EXPERIMENTAL
Intervention: Tizanidine (6 mg/day, increased to 18 mg/day based on response)
Number of subjects: 37
Study 1468911 — intervention group
Group type: EXPERIMENTAL
Intervention: Tizanidine
Number of subjects: 37
Study 1468911 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 3979577 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose danazol (100 mg/24 hours)
Number of subjects: 6
Study 3979577 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31746880 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein concentration with normal protein ratio (80 casein:20 whey)
Number of subjects: 0
Study 31746880 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein concentration with modified protein ratio (40 casein:60 whey)
Number of subjects: 0
Study 31746880 — intervention group
Group type: COMPARATOR
Intervention: Water-permeate control
Number of subjects: 0
Study 31746880 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein treatments (both ratios)
Number of subjects: 0
Study 29426272 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen supplementation (E2)
Number of subjects: 3
Study 29426272 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (access to running wheel)
Number of subjects: 3
Study 29426272 — intervention group
Group type: COMPARATOR
Intervention: Ovariectomized rats without estrogen
Number of subjects: 3
Study 27353847 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins and a CoQ analogue (experimental group)
Number of subjects: 45
Study 27353847 — intervention group
Group type: COMPARATOR
Intervention: Statins alone (control group)
Number of subjects: 45
Study 24626068 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcendental Meditation program
Number of subjects: 40
Study 24626068 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 40
Study 21906546 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-tailored intervention delivered on CD-ROM
Number of subjects: 442
Study 21906546 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-tailored intervention delivered in print
Number of subjects: 442
Study 21906546 — intervention group
Group type: COMPARATOR
Intervention: Generic information condition
Number of subjects: 442
Study 16214825 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine therapy
Number of subjects: 71
Study 16214825 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk group defined by ITPA 94C > A or TPMT <10 nmol/(mL erythrocytes . h)
Number of subjects: 71
Study 12109175 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Body Image: Teaching Kids to Eat and Love Their Bodies Too! curriculum
Number of subjects: 415
Study 12109175 — intervention group
Group type: COMPARATOR
Intervention: Control group (not exposed to the curriculum)
Number of subjects: 415
Study 9783399 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated trivalent influenza split vaccine (IIV)
Number of subjects: 600
Study 9783399 — intervention group
Group type: EXPERIMENTAL
Intervention: Live trivalent influenza allantoic vaccine (LIV)
Number of subjects: 600
Study 9783399 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined use of IIV and LIV
Number of subjects: 600
Study 9783399 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined vaccination (IIV + LIV)
Number of subjects: 600
Study 9783399 — intervention group
Group type: COMPARATOR
Intervention: Inactivated trivalent influenza split vaccine (IIV) alone
Number of subjects: 600
Study 9783399 — intervention group
Group type: COMPARATOR
Intervention: Live trivalent influenza allantoic vaccine (LIV) alone
Number of subjects: 600
Study 9783399 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination schedule with IIV followed by revaccination with LIV 3-4 weeks later
Number of subjects: 600
Study 8072991 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (600 mg and 1200 mg daily)
Number of subjects: 41
Study 8072991 — intervention group
Group type: COMPARATOR
Intervention: Diets
Number of subjects: 41
Study 8072991 — intervention group
Group type: COMPARATOR
Intervention: Predian
Number of subjects: 41
Study 8072991 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide
Number of subjects: 41
Study 8072991 — intervention group
Group type: COMPARATOR
Intervention: Sugar-reducing drugs and insulin
Number of subjects: 41
Study 3383879 — intervention group
Group type: EXPERIMENTAL
Intervention: Molsidomine (8 mg)
Number of subjects: 12
Study 3383879 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (20 mg)
Number of subjects: 12
Study 3383879 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 11685297 — intervention group
Group type: EXPERIMENTAL
Intervention: TLC C-53 (liposomal prostaglandin E1)
Number of subjects: 102
Study 11685297 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 31203726 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation of the renal main arteries
Number of subjects: 120
Study 31203726 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined radiofrequency ablation of the main and branch arteries
Number of subjects: 120
Study 31203726 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-based ablation of the main renal artery
Number of subjects: 120
Study 29603781 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron 50 mg
Number of subjects: 66
Study 29603781 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 27403645 — intervention group
Group type: EXPERIMENTAL
Intervention: saxagliptin 5 mg/d
Number of subjects: 100
Study 27403645 — intervention group
Group type: COMPARATOR
Intervention: placebo add-on
Number of subjects: 100
Study 24606097 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (40,000 IU weekly)
Number of subjects: 24
Study 24606097 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 22984018 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtotal or gross total resections
Number of subjects: 526
Study 22984018 — intervention group
Group type: COMPARATOR
Intervention: Biopsy
Number of subjects: 526
Study 19825207 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g dark chocolate with 500 mg polyphenols
Number of subjects: 14